1108 / 1851
Slotman B. et al. NEJM 2007;357
Role of PCI in ED-SCLC:
EORTC 22993 trial
Survival benefit = 13.8% @1 year
27.1% vs 13.3%
Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases
and prolongs disease-free and overall survival
N.B. response to chemotherapy (4-6 cycles)
mandatory to enter this study